Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CMP-CPS-001

Oligonucleotide (Antisense oligonucleotide) · Gene silencing · developed by CAMP4 Therapeutics

Phase 1 Most advanced trial

CAMP Developer

1 Registered trials

What is CMP-CPS-001?

CMP-CPS-001 is an antisense oligonucleotide solution administered subcutaneously. It is being studied in healthy volunteers and in ornithine transcarbamylase (OTC) deficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (Antisense oligonucleotide)
Mechanism: Gene silencing
Therapy area: Neurology
Developer: CAMP4 Therapeutics Corporation (CAMP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06247670	Phase 1	Healthy Volunteers	Active not recruiting	CAMP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy VolunteersOTC Deficiency

Sources

ClinicalTrials.gov NCT06247670

Updated Oct 11, 2026. Something wrong or missing? Report it on the CAMP page.

Follow CAMP, the company behind CMP-CPS-001

See CAMP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CAMP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z